Skip to main content
iwCLL 2025 Main banner
Final Program


Save The Date

    Arnon P. Kater, MD, PhD

    Vice Chair, Hematologist & Principal Scientist
    Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON
    Amsterdam, Noord-Holland, Netherlands

    Prof. Dr Arnon P. Kater, MD, PhD

    Translational Research:
    Professor Kater's translational research, conducted in collaboration with Professor Eric Eldering, is deeply embedded in the Laboratory of Experimental Immunology at Amsterdam UMC. Together, they focus on the intricate interactions between tumor cells and the adaptive immune system within the tumor microenvironment. Their pioneering studies have shed light on how CLL cells manipulate their surroundings to evade therapeutic interventions and immune responses. This research has led to the identification of high-risk genetic alterations and novel immune evasion mechanisms, providing a deeper understanding of the disease's pathology.
    A significant aspect of his work involves exploring the role of immunometabolism in T cell dysfunction. Supported by prestigious grants like the ERC Consolidator Grant and the European Society of Hematology Grant, his team have uncovered how CLL cells impair T cells, which are crucial for cancer defense. Their research highlights the critical link between T cell signaling and metabolic processes, opening new avenues for therapeutic interventions.
    Clinical Research:
    Professor Kater's clinical research focuses on implementing targeted agents and engaging autologous T cells to improve patient outcomes through time-limited therapy. His clinical studies span phase 1, 2, and 3 trials, both investigator-initiated and company-sponsored, demonstrating his commitment to translating laboratory insights into practical treatments.
    .
    Innovative Approaches:
    Professor Kater is also at the forefront of developing novel bispecific antibodies in combination with targeted agents. He is pioneering two HOVON trials in this area, aiming to further enhance treatment efficacy and patient outcomes.
    Through his groundbreaking research, Professor Kater has not only transformed CLL treatment paradigms but also broadened the impact of his findings to other B-cell malignancies.

    Presentation(s):

    Email Arnon